Apoptosis in human glioblastoma cells produced using embryonic stem cell-derived astrocytes expressing tumor necrosis factor-related apoptosis-inducing ligand

Isabelle M. Germano, Mahmud Uzzaman, Ronald Benveniste, Milana Zaurova, Gordon Keller

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Object. Embryonic stem (ES) cell-derived astrocytes have several theoretical and practical advantages as gene therapy vectors in the treatment of malignant gliomas. The aim of this study was to test the proapoptotic effects of ES cell-derived astrocytes expressing transgenic tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human malignant glioma cells. Methods. Mouse ES cells containing a doxycycline-inducible transgene were engineered with human TRAIL (hTRAIL) and then directed to differentiate into astrocytes. The ES cell-derived-TRAIL-expressing astrocytes were cocultured with human malignant glioma cells. Reverse transcriptase polymerase chain reaction, immunocytochemistry, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling, and flow cytometry were used to quantify results. In vitro coculture of ES cell-derived astrocytes expressing hTRAIL with A172 human malignant glioma cells after doxycycline induction caused a significant decrease in cell viability from 85 6 2% at baseline to 8 6 2% posttreatment (p < 0.001). Labeling with apoptotic markers showed that cell death occurred by means of apoptosis. A significant increase in apoptotic rate (88 ± 3%) from baseline (4 ± 2%) was found in A172 cells after doxycycline induction (p < 0.005). This effect was superior to the apoptotic rate seen after treatment with recombinant TRAIL (57 6 2%). A decrease in cell viability and an increase in the apoptotic rate were not found in TRAIL-expressing-ES cell-derived astrocytes after induction with doxycycline or in A172 cells exposed to doxycycline alone. Conclusions. Engineering of transgenic hTRAIL by using ES cell-derived astrocytes induced apoptosis in human malignant glioma cells while sparing nontumor astrocytes. The apoptotic effects of transgenic hTRAIL are greater than those of recombinant hTRAIL. Analysis of these results suggests that hTRAIL-expressing-ES cell-derived astrocytes should be considered in the development of new in vivo strategies to treat malignant human gliomas.

Original languageEnglish
Pages (from-to)88-95
Number of pages8
JournalJournal of Neurosurgery
Volume105
Issue number1
DOIs
StatePublished - Jul 7 2006
Externally publishedYes

Fingerprint

Glioblastoma
Embryonic Stem Cells
Astrocytes
Tumor Necrosis Factor-alpha
Apoptosis
Ligands
Glioma
Doxycycline
Cell Survival
Human Engineering
DNA Nucleotidylexotransferase
Coculture Techniques
Reverse Transcriptase Polymerase Chain Reaction
Transgenes
Genetic Therapy
Flow Cytometry
Cell Death
Immunohistochemistry
Therapeutics

Keywords

  • Astrocyte
  • Embryonic stem cell
  • Gene therapy
  • Malignant glioma
  • Tumor necrosis factor-related apoptosis-inducing ligand

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Apoptosis in human glioblastoma cells produced using embryonic stem cell-derived astrocytes expressing tumor necrosis factor-related apoptosis-inducing ligand. / Germano, Isabelle M.; Uzzaman, Mahmud; Benveniste, Ronald; Zaurova, Milana; Keller, Gordon.

In: Journal of Neurosurgery, Vol. 105, No. 1, 07.07.2006, p. 88-95.

Research output: Contribution to journalArticle

@article{604f29e93db5491594353cc513ee09f2,
title = "Apoptosis in human glioblastoma cells produced using embryonic stem cell-derived astrocytes expressing tumor necrosis factor-related apoptosis-inducing ligand",
abstract = "Object. Embryonic stem (ES) cell-derived astrocytes have several theoretical and practical advantages as gene therapy vectors in the treatment of malignant gliomas. The aim of this study was to test the proapoptotic effects of ES cell-derived astrocytes expressing transgenic tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human malignant glioma cells. Methods. Mouse ES cells containing a doxycycline-inducible transgene were engineered with human TRAIL (hTRAIL) and then directed to differentiate into astrocytes. The ES cell-derived-TRAIL-expressing astrocytes were cocultured with human malignant glioma cells. Reverse transcriptase polymerase chain reaction, immunocytochemistry, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling, and flow cytometry were used to quantify results. In vitro coculture of ES cell-derived astrocytes expressing hTRAIL with A172 human malignant glioma cells after doxycycline induction caused a significant decrease in cell viability from 85 6 2{\%} at baseline to 8 6 2{\%} posttreatment (p < 0.001). Labeling with apoptotic markers showed that cell death occurred by means of apoptosis. A significant increase in apoptotic rate (88 ± 3{\%}) from baseline (4 ± 2{\%}) was found in A172 cells after doxycycline induction (p < 0.005). This effect was superior to the apoptotic rate seen after treatment with recombinant TRAIL (57 6 2{\%}). A decrease in cell viability and an increase in the apoptotic rate were not found in TRAIL-expressing-ES cell-derived astrocytes after induction with doxycycline or in A172 cells exposed to doxycycline alone. Conclusions. Engineering of transgenic hTRAIL by using ES cell-derived astrocytes induced apoptosis in human malignant glioma cells while sparing nontumor astrocytes. The apoptotic effects of transgenic hTRAIL are greater than those of recombinant hTRAIL. Analysis of these results suggests that hTRAIL-expressing-ES cell-derived astrocytes should be considered in the development of new in vivo strategies to treat malignant human gliomas.",
keywords = "Astrocyte, Embryonic stem cell, Gene therapy, Malignant glioma, Tumor necrosis factor-related apoptosis-inducing ligand",
author = "Germano, {Isabelle M.} and Mahmud Uzzaman and Ronald Benveniste and Milana Zaurova and Gordon Keller",
year = "2006",
month = "7",
day = "7",
doi = "10.3171/jns.2006.105.1.88",
language = "English",
volume = "105",
pages = "88--95",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "1",

}

TY - JOUR

T1 - Apoptosis in human glioblastoma cells produced using embryonic stem cell-derived astrocytes expressing tumor necrosis factor-related apoptosis-inducing ligand

AU - Germano, Isabelle M.

AU - Uzzaman, Mahmud

AU - Benveniste, Ronald

AU - Zaurova, Milana

AU - Keller, Gordon

PY - 2006/7/7

Y1 - 2006/7/7

N2 - Object. Embryonic stem (ES) cell-derived astrocytes have several theoretical and practical advantages as gene therapy vectors in the treatment of malignant gliomas. The aim of this study was to test the proapoptotic effects of ES cell-derived astrocytes expressing transgenic tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human malignant glioma cells. Methods. Mouse ES cells containing a doxycycline-inducible transgene were engineered with human TRAIL (hTRAIL) and then directed to differentiate into astrocytes. The ES cell-derived-TRAIL-expressing astrocytes were cocultured with human malignant glioma cells. Reverse transcriptase polymerase chain reaction, immunocytochemistry, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling, and flow cytometry were used to quantify results. In vitro coculture of ES cell-derived astrocytes expressing hTRAIL with A172 human malignant glioma cells after doxycycline induction caused a significant decrease in cell viability from 85 6 2% at baseline to 8 6 2% posttreatment (p < 0.001). Labeling with apoptotic markers showed that cell death occurred by means of apoptosis. A significant increase in apoptotic rate (88 ± 3%) from baseline (4 ± 2%) was found in A172 cells after doxycycline induction (p < 0.005). This effect was superior to the apoptotic rate seen after treatment with recombinant TRAIL (57 6 2%). A decrease in cell viability and an increase in the apoptotic rate were not found in TRAIL-expressing-ES cell-derived astrocytes after induction with doxycycline or in A172 cells exposed to doxycycline alone. Conclusions. Engineering of transgenic hTRAIL by using ES cell-derived astrocytes induced apoptosis in human malignant glioma cells while sparing nontumor astrocytes. The apoptotic effects of transgenic hTRAIL are greater than those of recombinant hTRAIL. Analysis of these results suggests that hTRAIL-expressing-ES cell-derived astrocytes should be considered in the development of new in vivo strategies to treat malignant human gliomas.

AB - Object. Embryonic stem (ES) cell-derived astrocytes have several theoretical and practical advantages as gene therapy vectors in the treatment of malignant gliomas. The aim of this study was to test the proapoptotic effects of ES cell-derived astrocytes expressing transgenic tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human malignant glioma cells. Methods. Mouse ES cells containing a doxycycline-inducible transgene were engineered with human TRAIL (hTRAIL) and then directed to differentiate into astrocytes. The ES cell-derived-TRAIL-expressing astrocytes were cocultured with human malignant glioma cells. Reverse transcriptase polymerase chain reaction, immunocytochemistry, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling, and flow cytometry were used to quantify results. In vitro coculture of ES cell-derived astrocytes expressing hTRAIL with A172 human malignant glioma cells after doxycycline induction caused a significant decrease in cell viability from 85 6 2% at baseline to 8 6 2% posttreatment (p < 0.001). Labeling with apoptotic markers showed that cell death occurred by means of apoptosis. A significant increase in apoptotic rate (88 ± 3%) from baseline (4 ± 2%) was found in A172 cells after doxycycline induction (p < 0.005). This effect was superior to the apoptotic rate seen after treatment with recombinant TRAIL (57 6 2%). A decrease in cell viability and an increase in the apoptotic rate were not found in TRAIL-expressing-ES cell-derived astrocytes after induction with doxycycline or in A172 cells exposed to doxycycline alone. Conclusions. Engineering of transgenic hTRAIL by using ES cell-derived astrocytes induced apoptosis in human malignant glioma cells while sparing nontumor astrocytes. The apoptotic effects of transgenic hTRAIL are greater than those of recombinant hTRAIL. Analysis of these results suggests that hTRAIL-expressing-ES cell-derived astrocytes should be considered in the development of new in vivo strategies to treat malignant human gliomas.

KW - Astrocyte

KW - Embryonic stem cell

KW - Gene therapy

KW - Malignant glioma

KW - Tumor necrosis factor-related apoptosis-inducing ligand

UR - http://www.scopus.com/inward/record.url?scp=33745563200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745563200&partnerID=8YFLogxK

U2 - 10.3171/jns.2006.105.1.88

DO - 10.3171/jns.2006.105.1.88

M3 - Article

VL - 105

SP - 88

EP - 95

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 1

ER -